Kezar Life Sciences (KZR) News Today → A ‘DeFi Summer’ Projected! (From Crypto 101 Media) (Ad) Free KZR Stock Alerts $0.77 0.00 (0.00%) (As of 05/16/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 16 at 4:34 PM | investing.comKezar Life Sciences Inc (KZR)May 16 at 2:56 AM | americanbankingnews.comKezar Life Sciences, Inc. (NASDAQ:KZR) Short Interest UpdateMay 16 at 2:53 AM | marketbeat.comKezar Life Sciences, Inc. (NASDAQ:KZR) Short Interest Up 8.6% in AprilKezar Life Sciences, Inc. (NASDAQ:KZR - Get Free Report) was the recipient of a large increase in short interest during the month of April. As of April 30th, there was short interest totalling 4,150,000 shares, an increase of 8.6% from the April 15th total of 3,820,000 shares. Based on an average daily volume of 778,300 shares, the days-to-cover ratio is currently 5.3 days.May 14 at 2:08 AM | americanbankingnews.comKezar Life Sciences (NASDAQ:KZR) Stock Rating Reaffirmed by HC WainwrightMay 10, 2024 | markets.businessinsider.comHold Rating on Kezar Life Sciences Amid Trial Progress and Efficacy ConcernsMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Kezar Life Sciences Amid Promising Clinical Trials and Strong Financial PositionMay 10, 2024 | marketbeat.comKezar Life Sciences (NASDAQ:KZR) Given Buy Rating at HC WainwrightHC Wainwright reissued a "buy" rating and issued a $20.00 price objective on shares of Kezar Life Sciences in a research report on Friday.May 9, 2024 | msn.comKZR Stock Earnings: Kezar Life Sciences Beats EPS for Q1 2024May 9, 2024 | businesswire.comKezar Life Sciences Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 8, 2024 | americanbankingnews.comKezar Life Sciences (NASDAQ:KZR) Trading 3.1% Higher May 6, 2024 | businesswire.comKezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)April 16, 2024 | marketbeat.comKezar Life Sciences (NASDAQ:KZR) Trading Down 6.2%Kezar Life Sciences (NASDAQ:KZR) Stock Price Down 6.2%April 8, 2024 | businesswire.comKezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)March 27, 2024 | investorplace.comFrom Pennies to Fortunes: 3 Stocks Set to Make MillionairesMarch 18, 2024 | marketbeat.comHC Wainwright Reaffirms Buy Rating for Kezar Life Sciences (NASDAQ:KZR)HC Wainwright reissued a "buy" rating and issued a $20.00 target price on shares of Kezar Life Sciences in a research report on Friday.March 18, 2024 | marketbeat.comKezar Life Sciences, Inc. (NASDAQ:KZR) Short Interest Up 6.0% in FebruaryKezar Life Sciences, Inc. (NASDAQ:KZR - Get Free Report) saw a large growth in short interest during the month of February. As of February 29th, there was short interest totalling 3,180,000 shares, a growth of 6.0% from the February 14th total of 3,000,000 shares. Based on an average trading volume of 706,900 shares, the short-interest ratio is presently 4.5 days.March 16, 2024 | investorplace.comDiamonds in the Dust: 3 Penny Stocks Set to Soar 500% by 2026March 14, 2024 | investorplace.comKZR Stock Earnings: Kezar Life Sciences Misses EPS for Q4 2023March 14, 2024 | businesswire.comKezar Life Sciences Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business UpdateMarch 12, 2024 | finanznachrichten.deEverest Medicines' Partner Calliditas Therapeutics Announces U.S. FDA Grants an Additional Seven-Year Orphan Drug Exclusivity Period for NefeconMarch 3, 2024 | finance.yahoo.comKezar Life Sciences, Inc. (KZR)February 29, 2024 | marketbeat.comAcadian Asset Management LLC Has $988,000 Position in Kezar Life Sciences, Inc. (NASDAQ:KZR)Acadian Asset Management LLC lifted its position in shares of Kezar Life Sciences, Inc. (NASDAQ:KZR - Free Report) by 179.2% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 831,693 shares of the company's stockFebruary 28, 2024 | finance.yahoo.comKezar Life Sciences to Participate in the TD Cowen 44th Annual Health Care ConferenceFebruary 27, 2024 | markets.businessinsider.comBuy Rating Affirmed for Kezar Life Sciences Amidst Progress in Lupus Nephritis Treatment and Expansion into Chinese MarketFebruary 26, 2024 | businesswire.comEverest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus NephritisFebruary 26, 2024 | prnewswire.comEverest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus NephritisFebruary 25, 2024 | investorplace.com3 Top Penny Stocks for 5,000% Upside in 2024 and BeyondFebruary 22, 2024 | benzinga.comKezar Life Sciences Stock (NASDAQ:KZR) Dividends: History, Yield and DatesFebruary 19, 2024 | thestreet.comKezar Life Sciences Inc.February 10, 2024 | finance.yahoo.com3 Penny Stocks Poised for an Unbelievable 1,000% JumpJanuary 31, 2024 | morningstar.comKezar Life Sciences Inc KZRJanuary 18, 2024 | finance.yahoo.comKZR Jan 2025 17.500 callDecember 26, 2023 | finance.yahoo.comBull Run Bonanza: Top 3 Penny Stocks Primed for Explosive GrowthDecember 5, 2023 | msn.comEverest inches towards clinical studies for renal disease drug in ChinaNovember 27, 2023 | markets.businessinsider.comBuy Rating Affirmed: Kezar Life Sciences’ Promising Trials and Strong FinancialsNovember 27, 2023 | markets.businessinsider.comAnalyst Expectations for Kezar Life Sciences's FutureNovember 21, 2023 | finance.yahoo.comKezar Life Sciences to Present at the 6th Annual Evercore ISI HealthCONx ConferenceNovember 14, 2023 | benzinga.comKezar Life Sciences Stock (NASDAQ:KZR), Analyst Ratings, Price Targets, PredictionsNovember 13, 2023 | finance.yahoo.comKezar Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business UpdateOctober 23, 2023 | finance.yahoo.com12 Best Penny Stocks to Buy Under $1October 13, 2023 | nasdaq.comHC Wainwright & Co. Reiterates Kezar Life Sciences (KZR) Buy RecommendationOctober 12, 2023 | markets.businessinsider.comRestructuring and Clinical Progress Bolster Kezar Life Sciences’ Buy Rating: An AnalysisOctober 5, 2023 | msn.comJonesTrading Downgrades Kezar Life Sciences (KZR)October 5, 2023 | seekingalpha.comKezar Life Sciences names new CEO, says to cut workforce by about 41%October 3, 2023 | marketbeat.comTrading was temporarily halted for "KZR" at 04:10 PM with a stated reason of "News pending."September 25, 2023 | markets.businessinsider.comKezar Life Sciences’ Potential High Returns and Extended Lifespan through Everest Medicines Collaboration: A Buy Rating AnalysisSeptember 21, 2023 | msn.comKezar and Everest enter lupus nephritis therapy development dealSeptember 20, 2023 | marketwatch.comKezar Life Sciences Shares Rise After Deal With Everest MedicinesSeptember 20, 2023 | businesswire.comKezar Life Sciences and Everest Medicines Enter into an Agreement to Develop and Commercialize Zetomipzomib for Lupus Nephritis and other Potential Indications in Greater China ...September 20, 2023 | finance.yahoo.comKezar Life Sciences and Everest Medicines Enter into an Agreement to Develop and Commercialize Zetomipzomib for Lupus Nephritis and other Potential Indications in Greater China, South Korea and Southeast Asia Get Kezar Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for KZR and its competitors with MarketBeat's FREE daily newsletter. Email Address Why Is Gold On a MASSIVE rally? (Ad)Gold has been on a tear this year. The yellow metal has hit an all-time high of $2,4231.29 recently and the rally could be far from over. From central banks to even Costco customers, it seems everyone is buying gold these days. With Wall Street watching the gold space carefully, now is a perfect time to pay attention to this stock. This Little known Company is a uniquely structured for profit KZR Media Mentions By Week KZR Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KZR News Sentiment▼0.810.55▲Average Medical News Sentiment KZR News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KZR Articles This Week▼121▲KZR Articles Average Week Get Kezar Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for KZR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: EGRX News Today CKPT News Today AEON News Today ALRN News Today EQ News Today CALC News Today KRON News Today ANVS News Today IMMX News Today RPHM News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:KZR) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersGold Set to EXPLODE!Gold Safe ExchangeWhy Is Gold On a MASSIVE rally? Huge AlertsThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingHow Biden has already won 2024Porter & CompanyCharles Payne Demystifies OptionsUnstoppable ProsperityBiden FINISHED On June 13th?Paradigm PressBiden Nomination CANCELED?The Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kezar Life Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
